16 July 2026 | 12:49PM HKT Equity Research Ascletis Pharma Inc. (1672.HK): ASC30 global ph3 scheduled in September; eyes on dosing strategy / BD updates Global ph3 cleared for ASC30: On July 16th, we attended a business update call for Ascletis, during which mgmt shared the latest update on the global development plan for ASC30 (oral GLP-1). The global ph3 trial for ASC30 in obesity was recently cleared by the FDA, and is scheduled to initiate this September, which is in accordance with the previous guidanc ...